Lucia Motta
Papers
1
Total Citations
6
H-Index
1
About
Dr. Lucia Motta is a leading clinical researcher in urologic oncology, with a focused expertise in prostate cancer diagnostics and post-treatment surveillance. Her major contributions center on improving the early detection of biochemical recurrence (BCR) after radical prostatectomy—a critical challenge in managing prostate cancer. In her landmark 2019 prospective cohort study, Dr. Motta demonstrated that the serum biomarker p2PSA can identify BCR significantly earlier than conventional total PSA testing, addressing an unmet clinical need for more sensitive and specific surveillance tools. This work, which has garnered 6 citations, provides compelling evidence that p2PSA may enable clinicians to detect clinically significant recurrent prostate cancer at a much earlier stage, potentially guiding more timely therapeutic interventions. Dr. Motta’s research is notable for its direct translational impact, bridging the gap between biomarker discovery and practical postoperative monitoring. Her findings have implications for reducing unnecessary treatments and improving patient outcomes, positioning her as a key voice in the evolution of precision oncology for prostate cancer.
Research Focus
Key Achievements
Top Papers
- 1